BMS Downsizes In China Amid Slow Sales, Regulatory Uncertainty
This article was originally published in PharmAsia News
BMS is slashing staff and operations in China to focus on selected areas in a harsh post-GSK affair business environment, while regulatory uncertainty underscored by China’s review of multi-regional clinical trials may be hurting the company even more, says an industry analyst.
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.